173 related articles for article (PubMed ID: 25119002)
1. Risk factors for intraocular involvement in patients with primary central nervous system lymphoma.
Cho BJ; Yu HG
J Neurooncol; 2014 Dec; 120(3):523-9. PubMed ID: 25119002
[TBL] [Abstract][Full Text] [Related]
2. Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma.
Zhuang L; Lai J; Chen K; Ding T; Yuan Y; Ma Y; Kang H; Lin Z; Fan N; Ma J; Zeng Q; Xu X; Wang Q; Chen B
Oncol Rep; 2019 Jan; 41(1):397-404. PubMed ID: 30320386
[TBL] [Abstract][Full Text] [Related]
3. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.
Grimm SA; McCannel CA; Omuro AM; Ferreri AJ; Blay JY; Neuwelt EA; Siegal T; Batchelor T; Jahnke K; Shenkier TN; Hall AJ; Graus F; Herrlinger U; Schiff D; Raizer J; Rubenstein J; Laperriere N; Thiel E; Doolittle N; Iwamoto FM; Abrey LE
Neurology; 2008 Oct; 71(17):1355-60. PubMed ID: 18936428
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of primary central nervous system and primary intraocular lymphomas.
Tuaillon N; Chan CC
Curr Mol Med; 2001 May; 1(2):259-72. PubMed ID: 11899075
[TBL] [Abstract][Full Text] [Related]
5. [The clinical findings and prognosis of 28 cases of intraocular lymphoma].
Kimura K; Goto H
Nippon Ganka Gakkai Zasshi; 2008 Aug; 112(8):674-8. PubMed ID: 18767492
[TBL] [Abstract][Full Text] [Related]
6. Primary central nervous system lymphoma: a study of clinicopathological features and trend in western India.
Pasricha S; Gupta A; Gawande J; Trivedi P; Patel D
Indian J Cancer; 2011; 48(2):199-203. PubMed ID: 21768666
[TBL] [Abstract][Full Text] [Related]
7. Relevance of intraocular involvement in the management of primary central nervous system lymphomas.
Ferreri AJ; Blay JY; Reni M; Pasini F; Gubkin A; Tirelli U; Calderoni A; Zucca E; Cortelazzo S; Chassagne C; Tinguely M; Borisch B; Berger F; Ponzoni M; Cavalli F;
Ann Oncol; 2002 Apr; 13(4):531-8. PubMed ID: 12056702
[TBL] [Abstract][Full Text] [Related]
8. Are there primary intraocular lymphomas that do not develop into central nervous system lymphomas?
Matsuo T; Tanaka T
J Clin Exp Hematop; 2019 Dec; 59(4):168-174. PubMed ID: 31611509
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of High Ki-67 Index and Histogenetic Subclassification in Primary Central Nervous System Lymphoma.
Cho U; Oh WJ; Hong YK; Lee YS
Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):254-262. PubMed ID: 27490760
[TBL] [Abstract][Full Text] [Related]
10. Ocular manifestation of primary nervous system lymphoma: what can be expected from imaging?
Küker W; Herrlinger U; Grönewäller E; Rohrbach JM; Weller M
J Neurol; 2002 Dec; 249(12):1713-6. PubMed ID: 12529795
[TBL] [Abstract][Full Text] [Related]
11. Biology and treatment of primary central nervous system lymphoma.
Algazi AP; Kadoch C; Rubenstein JL
Neurotherapeutics; 2009 Jul; 6(3):587-97. PubMed ID: 19560747
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and Outcomes of Primary Central Nervous System Lymphoma: A Retrospective Study of 91 Cases in a Chinese Population.
Mao C; Chen F; Li Y; Jiang X; Liu S; Guo H; Huang L; Wei X; Liang Z; Li W; Tang K
World Neurosurg; 2019 Mar; 123():e15-e24. PubMed ID: 30326304
[TBL] [Abstract][Full Text] [Related]
13. Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands.
van der Sanden GA; Schouten LJ; van Dijck JA; van Andel JP; van der Maazen RW; Coebergh JW;
Cancer; 2002 Mar; 94(5):1548-56. PubMed ID: 11920513
[TBL] [Abstract][Full Text] [Related]
14. Primary central nervous system lymphomas in immunocompetent individuals: histology, Epstein-Barr virus genome, Ki-67 proliferation index, p53 and bcl-2 gene expression.
Krogh-Jensen M; Johansen P; D'Amore F
Leuk Lymphoma; 1998 Jun; 30(1-2):131-42. PubMed ID: 9669683
[TBL] [Abstract][Full Text] [Related]
15. Eye involvement in primary central nervous system lymphoma.
Farrall AL; Smith JR
Surv Ophthalmol; 2020; 65(5):548-561. PubMed ID: 32057762
[TBL] [Abstract][Full Text] [Related]
16. Ocular involvement in patients with primary CNS lymphoma.
Hong JT; Chae JB; Lee JY; Kim JG; Yoon YH
J Neurooncol; 2011 Mar; 102(1):139-45. PubMed ID: 20658258
[TBL] [Abstract][Full Text] [Related]
17. Second malignancies in patients with primary central nervous system lymphoma.
Wang J; Pulido JS; O'Neill BP; Johnston PB
Neuro Oncol; 2015 Jan; 17(1):129-35. PubMed ID: 24948826
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of clinical characteristics and immunophenotypic biomarkers in 115 patients with primary central nervous system lymphoma.
Chen BB; Xu XP; Shen L; Han TJ; Lin ZG; Chen Z; Kang H; Huang B; Lin GW
Chin Med J (Engl); 2013 Feb; 126(3):482-7. PubMed ID: 23422111
[TBL] [Abstract][Full Text] [Related]
19. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement.
Smith JR; Rosenbaum JT; Wilson DJ; Doolittle ND; Siegal T; Neuwelt EA; Pe'er J
Ophthalmology; 2002 Sep; 109(9):1709-16. PubMed ID: 12208721
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography.
Kim HO; Kim JS; Kim SO; Chae SY; Oh SJ; Seo M; Lee SH; Oh JS; Ryu JS; Huh JR; Kim JH
Medicine (Baltimore); 2020 May; 99(20):e20140. PubMed ID: 32443328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
